The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).
 
Elizabeth M. Burton
No Relationships to Disclose
 
Timothy Woody
No Relationships to Disclose
 
Isabella Claudia Glitza
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Lilly
 
Rodabe Navroze Amaria
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Emily Zhi-Yun Keung
No Relationships to Disclose
 
Adi Diab
Consulting or Advisory Role - Celgene; CureVac; Nektar
Research Funding - Celgene (Inst); Idera (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar
 
Sapna Pradyuman Patel
Consulting or Advisory Role - Cardinal Health; Castle Biosciences; Incyte
Speakers' Bureau - Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Provectus (Inst); Reata Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Cardinal Health; Castle Biosciences; Incyte; Massachusetts General Hospital; PCME, Rockpointe; Socrates Analytics
 
Michael K.K. Wong
Consulting or Advisory Role - Merck; Pfizer
 
Cassian Yee
Consulting or Advisory Role - Adaptive Biotechnologies; Immatics
Patents, Royalties, Other Intellectual Property - Invention for use of IL21
 
Patrick Hwu
Stock and Other Ownership Interests - Immatics
Consulting or Advisory Role - Dragonfly Therapeutics; GlaxoSmithKline; Immatics; Sanofi
Research Funding - Genentech (Inst)
 
Jennifer Leigh McQuade
No Relationships to Disclose
 
Scott Eric Woodman
No Relationships to Disclose
 
Michael T. Tetzlaff
Consulting or Advisory Role - Myriad Genetics; Novartis
 
Michael A. Davies
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; NanoString Technologies; Novartis; Sanofi; Syndax; Vaccinex
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst)
 
Jennifer Ann Wargo
Leadership - Microbiome DX
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Dava Oncology; Genentech; Gilead Sciences; GlaxoSmithKline; Illumina; Merck; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck; Novartis
Speakers' Bureau - Dava Oncology; Genentech; Illumina; Novartis; PER; Precision Health Economics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; Genentech; GlaxoSmithKline; Illumina; Novartis
 
Kunal Rai
No Relationships to Disclose
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)